IRCT20200105046010N93招募中未知
Bioequivalence study of Empagliflozin/Metformin12.5/1000 mg ( EMZIP® 12.5/1000 mg) manufactured by Faran pharmed versus originator brand SYNJARDY® 12.5/1000 mg manufactured by ??Boehringer ????? Co in fasting condition in healthy volunteers
Faran Pharmed company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcoholism and Narcoticism
- •History of allergy to Empagliflozin/Metformin
研究者
相似试验
招募中
Unknown
Bioequivalence study of Empagliflozin Metformin 12.5-1000 mgBioequivalence study of Empagliflozin Metformin 12.5-1000 mg (Tehran Chemie Pharmaceutical Company) versus Synjiardy(Boehringer Ingelheim) Tablet after single oral dosing in healthy volunteers.IRCT20220111053692N17Tehran Chemie Pharmaceutical Company24
招募中
Unknown
Investigating the in vivo bioequivalence of Empagliflozin /Metformin tabletIRCT20210519051345N31Tabriz University of Medical Sciences24
已完成
1 期
Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate TabletsHealthyNCT02028767Boehringer Ingelheim32
已完成
1 期
Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered TogetherHealthyNCT01811953Boehringer Ingelheim48
已完成
Unknown
Comparative in vivo evaluation of 2 Empagliflozin 12.5 Combined Tablet with Metformin 1000 mg Tablet formulations.IRCT20180620040164N52Darou darman Pars Co.24